Home | About the eMC | Help | Mobile

eMC - trusted, up to date and comprehensive information about medicines

Search medicine/company name only

Search full document

Advanced search

Medicine name A-Z | Active ingredient A-Z | Pharmaceutical company A-Z | Latest medicine updates | Yellow card report

Alliance Pharmaceuticals

Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB

Telephone: +44 (0)1249 466 966
Fax: +44 (0)1249 466 977
WWW: http://www.alliancepharma.co.uk
Medical Information e-mail: medinfo@alliancepharma.co.uk

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 15/08/2011

SPC	Anbesol Teething Gel

Table of Contents

1. NAME OF THE MEDICINAL PRODUCT
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
3. PHARMACEUTICAL FORM
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
4.2 Posology and method of administration
4.3 Contraindications
4.4 Special warnings and precautions for use
4.5 Interaction with other medicinal products and other forms of interaction
4.6 Pregnancy and lactation
4.7 Effects on ability to drive and use machines
4.8 Undesirable effects
4.9 Overdose
5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
5.2 Pharmacokinetic properties
5.3 Preclinical safety data
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
6.2 Incompatibilities
6.3 Shelf life
6.4 Special precautions for storage
6.5 Nature and contents of container
6.6 Special precautions for disposal and other handling
7. MARKETING AUTHORISATION HOLDER
8. MARKETING AUTHORISATION NUMBER(S)
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
10. DATE OF REVISION OF THE TEXT

Go to top of the page

1. NAME OF THE MEDICINAL PRODUCT

Anbesol Teething Gel

Go to top of the page

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Lidocaine hydrochloride	1.0%w/w
Chlorocresol	0.1%w/w
Cetylpyridinium chloride	0.02%w/w

Go to top of the page

3. PHARMACEUTICAL FORM

Gel for oral administration.

Go to top of the page

4. CLINICAL PARTICULARS

Go to top of the page

4.1 Therapeutic indications

For the temporary relief of pain caused by recurrent mouth ulcers, denture irritation and teething.

Go to top of the page

4.2 Posology and method of administration

Adults, children and the elderly: Apply a small amount to the affected area with a clean fingertip. Two applications immediately will normally be sufficient to obtain pain relief. Use up to four times a day.

Babies teething: Apply a small amount to the affected area with a clean fingertip. Use up to four times a day.

Go to top of the page

4.3 Contraindications

In patients with a known history of hypersensitivity or allergic type reactions to any of the constituents of the product.

Go to top of the page

4.4 Special warnings and precautions for use

The following statements will appear on the packaging:

If symptoms persist for more than 7 days, consult your doctor or dentist.

Keep all medicines out of the reach of children.

Go to top of the page

4.5 Interaction with other medicinal products and other forms of interaction

None known.

Go to top of the page

4.6 Pregnancy and lactation

No special precautions required.

Go to top of the page

4.7 Effects on ability to drive and use machines

None known.

Go to top of the page

4.8 Undesirable effects

There have been reports of non-specific ulceration following oral cetylpyridinium chloride therapy.

Go to top of the page

4.9 Overdose

Overdose is extremely unlikely considering the small size of the tube used for sale.

Go to top of the page

5. PHARMACOLOGICAL PROPERTIES

Go to top of the page

5.1 Pharmacodynamic properties

Lidocaine is a local anaesthetic of the amide type which acts by reversible inhibition of nerve impulse generation and transmission.

Chlorocresol: Chlorocresol has a disinfectant action.

Cetylpyridinium chloride: Cetylpyridinium chloride has a disinfectant action.

Go to top of the page

5.2 Pharmacokinetic properties

Lidocaine hydrochloride

Absorption and fate: Lidocaine is readily absorbed from mucous membranes and through damaged skin. Lidocaine undergoes first-pass metabolism in the liver and about 90% is dealkylated to form monoethylglycinexylidide and glycinexylidide. Further metabolism occurs and the metabolites are excreted in the urine with less than 10% as unchanged lidocaine.

Chlorocresol

Absorption: There is no significant absorption of chlorocresol through the skin or mucous membranes.

Cetylpyridinium chloride

Absorption: There is no significant absorption of cetylpyridinium chloride through the skin or mucous membranes.

Go to top of the page

5.3 Preclinical safety data

The active ingredients in Anbesol Teething Gel have a well established safety record.

Go to top of the page

6. PHARMACEUTICAL PARTICULARS

Go to top of the page

6.1 List of excipients

Alcohol 96%